ODQ 

ODQ is a potent and selective soluble guanylyl cyclase (sGC, nitric oxide-activated enzyme) inhibitor. ODQ enhances the pro-apoptotic effects of Cisplatin in human mesothelioma cells^[1].

At 30 and 50 μM, ODQ causes significant induction of apoptosis in the NCI-H2452 cells, elevating apoptotic levels by 12 fold and 15 fold, respectively. At 10μM, a concentration below the threshold for induction of apoptosis by ODQ, ODQ in combination with Cisplatin enhanced (in fact, doubled) the pro-apoptotic effects of Cisplatin at 1 μM^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

ODQ (2 mg/kg; i.p.) reduces the multiple organ injury and dysfunction caused by wall fragments of Gram-positive or Gram-negative bacteria in the anesthetized rat^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

187.15

Solid

C₉H₅N₃O₂

41443-28-1

O=C1ON=C2N1C3=C(C=CC=C3)N=C2

Room temperature in continental US; may vary elsewhere.

• [1]. Ronald Fiscus, et al. ODQ, an inhibitor of soluble guanylyl cyclase (nitric oxide-activated enzyme), enhances the pro-apoptotic effects of cisplatin in human mesothelioma cells. Cancer Res May 1 2007 (67) (9 Supplement) LB-43.

  [2]. Zacharowski K, et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit Care Med. 2001;29(8):1599-1608.  [Content Brief]